Synchron Raises $200M to Advance Non-Surgical Brain-Computer Interface
Synchron announced it has secured $200 million in a Series D funding round to expand operations and speed up commercialization of its non-surgical brain-computer interface (BCI) designed for people with paralysis.
Funding Details and Investors
The funding round was led by Double Point Ventures, joined by existing investors including Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Additional participants were the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
This latest investment increases Synchron’s total capital raised to $345 million, reflecting growing momentum in the brain-computer interface sector.
Industry Context and Recent Developments
Earlier this week, Precision Neuroscience, another BCI company focused on paralysis, announced a partnership with SCI Ventures, backed by the Christopher & Dana Reeve Foundation, to advance its Layer 7 Cortical Interface.
Last month, a study demonstrated that Science Corp.’s PRIMA BCI retinal implant partially restored vision for patients with severe age-related macular degeneration.
Synchron announced Thursday, Nov.: "Double Point Ventures led the round and was joined by existing investors Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI and Metis."
Precision Neuroscience revealed a partnership "to advance its Layer 7 Cortical Interface," supported by the Christopher & Dana Reeve Foundation.
Synchron’s substantial funding round highlights the increasing investment and innovation in non-invasive brain-computer technology aimed at improving lives of people with paralysis.